The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 156,413 | 729,303 | - | - |
| Cost of product sales | 5,377 | 14,507 | - | - |
| Acquired in-process research and development | 697,761 | - | - | - |
| Research and development (excluding stock-based compensation)-Navenibart | 9,741 | - | - | - |
| Research and development (excluding stock-based compensation)-Berotralstat | - | 4,323 | - | - |
| Research and development (excluding stock-based compensation)-BCX17725 | 1,907 | 9,996 | - | - |
| Research and development (excluding stock-based compensation)-Berotralstat | 1,796 | - | - | - |
| Research and development (excluding stock-based compensation)-Avoralstat | 893 | 9,497 | - | - |
| Research and development (excluding stock-based compensation)-Factor DProgram | - | -1,033 | - | - |
| Research and development (excluding stock-based compensation)-STAR0310 | 683 | - | - | - |
| Research and development (excluding stock-based compensation)-Research Discovery And Preclinical Programs | 3,970 | 17,677 | - | - |
| Research and development (excluding stock-based compensation)-Compensation And Related Personnel Costs | 27,091 | 51,576 | - | - |
| Research and development (excluding stock-based compensation)-Other Expenses1 | 7,419 | 27,958 | - | - |
| Sales and marketing (excluding stock-based compensation) | 42,953 | 94,616 | - | - |
| General and administrative (excluding stock-based compensation) | 42,393 | 116,006 | - | - |
| Stock-based compensation | 16,027 | 85,066 | - | - |
| Interest income | 2,256 | 10,668 | - | - |
| Interest expense | 19,779 | 55,378 | - | - |
| Foreign currency losses (gains), net | -225 | -152 | - | - |
| Loss on extinguishment of debt | - | -17,332 | - | - |
| Other expense, net | -1,462 | 12,090 | - | - |
| Income tax expense | 1,004 | 2,804 | - | - |
| Net (loss) income | -721,812 | 263,829 | - | - |
| Depreciation | 461 | - | - | - |
| Acquired in-process research and development | 697,761 | - | - | - |
| Depreciation and amortization | - | 1,058 | - | - |
| Amortization of assembled workforce | 600 | - | - | - |
| Inventory obsolescence | 74 | 776 | - | - |
| Stock-based compensation expense | 16,027 | 63,698 | - | - |
| Equity modification associated with sale of biocryst ireland | - | 17,548 | - | - |
| Mark-to-market adjustment on share-based liability | -2,807 | 4,313 | - | - |
| Payment of pharmakon pik interest | - | 23,704 | - | - |
| Non-cash interest expense on royalty financing obligations | 13,294 | 53,163 | - | - |
| Non-cash interest expense on secured term loan and amortization of debt issuance costs | - | -12,671 | - | - |
| Amortization of debt issuance costs on term loans | 149 | - | - | - |
| Amortization of premium (discount) on investments, net | 251 | -2,948 | - | - |
| Loss on extinguishment of debt | - | -17,332 | - | - |
| Loss on impairment | - | 0 | - | - |
| Gain on sale of non-financial asset | - | 550 | - | - |
| Gain on sale of biocryst ireland | - | 3,566 | - | - |
| Increase in receivables | 474 | 22,819 | - | - |
| Increase in inventory | 4,847 | 769 | - | - |
| Decrease (increase) in prepaid expenses and other assets | -3,532 | 7,695 | - | - |
| Decrease in royalty financing obligations | -8,470 | 68,428 | - | - |
| Decrease in accounts payable and accrued expenses | -60,395 | 104,945 | - | - |
| Decrease in deferred revenue | -749 | 0 | - | - |
| Net cash used in operating activities | -61,791 | 291,960 | - | - |
| Acquisitions of property and equipment | 403 | 2,325 | - | - |
| Purchases of investments | 0 | 213,478 | - | - |
| Sales and maturities of investments | 221,235 | 180,647 | - | - |
| Sale of non-financial asset | - | 550 | - | - |
| Proceeds from sale of biocryst ireland, net of cash divested | - | -6,183 | - | - |
| Acquisition of astria therapeutics, inc., net of cash acquired | 489,480 | - | - | - |
| Net cash (used in) provided by investing activities | -268,648 | -83,488 | - | - |
| Net proceeds from common stock issued under stock-based compensation plans | 19,479 | 6,725 | - | - |
| Withholding taxes paid on stock-based awards | 1,187 | 7,496 | - | - |
| Common stock issued to directors in lieu of cash retainer | 33 | 59 | - | - |
| Proceeds from issuance of long-term debt | 400,000 | 0 | - | - |
| Repayment of principal on term loans | - | 300,000 | - | - |
| Prepayment premium and fees on term loans | - | 9,886 | - | - |
| Payment of debt issuance costs on term loan | 4,952 | 0 | - | - |
| Principal payments on royalty financing obligations | 476 | 22,883 | - | - |
| Payment of royalty release fees | - | 15,500 | - | - |
| Principal payments on finance lease liabilities | 345 | 1,473 | - | - |
| Net cash provided by financing activities | 412,552 | -217,960 | - | - |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -72 | -72 | - | - |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Continuing Operations | - | - | -4,086 | -1,340 |
| Net increase in cash, and cash equivalents, and restricted cash | 82,041 | -15,544 | - | - |
| Less cash and cash equivalents classified within current assets held for sale | - | - | -218 | 15,058 |
| Beginning of period | 91,337 | 106,323 | - | - |
| Net decrease in cash, and cash equivalents, and restricted cash | - | - | -3,868 | -16,398 |
| End of period | 173,378 | 91,337 | - | - |
BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX)